Is hyperthermia combined with radiotherapy adequate in elderly patients with muscle-invasive bladder cancers? Thermo-radiobiological implications from an audit of initial results. (18th May 2016)

• Record Type: Journal Article
• Authors: Datta, Niloy R.; Eberle, Brigitte; Puric, Emsad; Meister, Andreas; Marder, Dietmar; Tim, Olaf; Klimov, Anton; Bodis, Stephan
• Is Part Of: International journal of hyperthermia. Volume 32:Number 4(2016)
• Page Start: 390
• Page End: 397
• Publication Date: 2016-05-18
• Subjects: Chemotherapy -- hyperthermia -- muscle-invasive bladder cancers -- radiotherapy -- thermal radiobiology; Thermotherapy -- Periodicals; 615.832
• DOI: 10.3109/02656736.2015.1132340
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Purpose : The aim of this study was to evaluate the outcomes of loco-regional hyperthermia (HT) with radiotherapy (RT) and/or chemotherapy (CT) in elderly patients with muscle-invasive bladder cancers (MIBC). Material and methods : Twenty consecutive MIBC patients were treated with HTRT ( n = 8) or HTCTRT ( n = 12) following transurethral resection of their bladder tumours. Weekly HT was administered prior to RT to a mean temperature of 40.6–42.7 °C for 60 min. A mean RT dose of 54.6 Gy (SD ± 4.2) was delivered. Single-agent cisplatin ( n = 2) or carboplatin ( n = 10) was used in HTCTRT patients. Results : The median age was 81 years. HTRT patients received a mean RT dose of 51.0 Gy compared to 57.1 Gy with HTCTRT ( p < 0.001) in a shorter overall treatment time (OTT) (30.8 ± 6.9 versus 43.9 ± 4.0 days, p < 0.001). All HTRT patients had long-term local disease control, while 41.6% of HTCTRT recurred during follow-up. None of the HTRT patients experienced grade III/IV acute and late toxicities, while these were evident in two and one HTCTRT patients respectively. Taken together, the 3-year bladder preservation, local disease-free survival, cause-specific survival and overall survival were 86.6%, 60.7%, 55% and 39.5% respectively. Even though the mean biological effective dose (BED) for both groups was similar (57.8 Gy15 ), the thermo-radiobiological BED estimated from HT-induced reduction of α/β was significantly higher for HTRT patients (91 ± 4.4 versus 85.8 ± 4.3 Gy3, p = 0.018). Conclusions : Thermal radiosensitisation with consequent reduction in α/β results in a higher thermo-radiobiological BED with a relatively higher RT dose/fraction and shorter OTT. This translates into a favourable outcome in elderly MIBC patients. Any benefit of CT in these patients needs further investigation.